PARP Imaging with [18F]Florathanatrace for Cancer

Recruiting in Palo Alto (17 mi)

Overseen byFarrokh Dehdashti, M.D.

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase < 1

Waitlist Available

Sponsor: Washington University School of Medicine

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial uses a special scan and a new radioactive substance to measure an enzyme's activity in cancer cells. It aims to help identify which cancer patients will benefit from specific treatments and ensure they get the right dose.

Eligibility Criteria

This trial is for adults with a tumor at least 1 cm in size, or healthy volunteers without cardiopulmonary issues (for different study arms). It's open to those with certain cancers treatable by platinum-based chemo. People can't join if they can't follow the study plan, stay still in a PET/CT scanner, have incompatible implants, non-measurable disease under 1 cm, or conditions like claustrophobia that prevent imaging sessions.

Inclusion Criteria

I am 18 years old or older.

I have a tumor that is at least 1 cm wide, confirmed by a CT scan.

I am healthy, don't smoke, and have no heart or lung issues needing treatment.

See 1 more

Exclusion Criteria

Presence of an implanted device that is incompatible with CT scanning

I understand and am willing to follow the study's instructions.

You have a history of feeling very uncomfortable or anxious in small spaces, like an MRI machine, or any other condition that would make it difficult for you to complete required imaging sessions.

See 2 more

Treatment Details

Interventions

[18F]FluorThanatrace (PARP-1 Inhibitor)

Trial Overview[18F]FluorThanatrace ([18F]FTT), a new radioactive tracer for PET scans, is being tested to see if it can effectively image cancer activity related to an enzyme called PARP-1. The trial will assess how well this compound works for visualizing tumors in patients.

Participant Groups

2Treatment groups

Experimental Treatment

Group I: Kinetic Studies ArmExperimental Treatment1 Intervention

An additional 30 participants with cancer will undergo a 1-hour dynamic scan upon injection of \[18F\]FluorThanatrace to determine the kinetics of the tracer in tumors to correlate with tissue-based markers of PARP activity and to obtain metabolite information to help determine the best quantification approach for the PET images. When possible these subjects will also undergo 18F-FDG imaging for comparison to tumor metabolism

Group II: Dosimetry Studies ArmExperimental Treatment1 Intervention

Twelve participants with cancer and eight healthy volunteers will be recruited first to undergo whole-body PET/CT imaging to determine the whole body dosimetry of \[18F\]FluorThanatrace.